Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Neal Ready et al.|European Journal of Cancer|2018Cited by 267
Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinomaDian Wang, J. Frank Wilson, Christopher J. Schultz et al.|International Journal of Radiation Oncology*Biology*Physics|2006Cited by 153
Clinical Outcomes of Patients Receiving Integrated PET/CT-Guided Radiotherapy for Head and Neck CarcinomaMatthew R. Vernon, Dian Wang, Mohit Maheshwari et al.|International Journal of Radiation Oncology*Biology*Physics|2008Cited by 93